Evaluation of the Efficacy and Tolerability of the Tested Formula 2039125 03 BID After 3 Months in the Treatment of Facial Hyperpigmentation of 3 Origins: Melasma, Acne Induced Post-Inflammatory Hyperpigmentation and Solar Lentigo
Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
The objective of this study is to evaluate the efficacy, cosmetic acceptability and improvement of the stigmatization of the tested product (2039125 03) used bis in die (BID) for 3 months in adult patients suffering from mild to moderate melasma, or mild to moderate acne induced post-inflammatory hyperpigmentation, or solar lentigo.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:
• all phototypes
• only one of the following pigmentary conditions on the face: epidermal or mixed, mild to moderate melasma; mild to moderate acne-induced PIHP; solar lentigo
• female patient of childbearing potential must use one of the reliable methods of contraception and agree not to change it during the study.
Locations
Other Locations
Portugal
PhDTrials Center
RECRUITING
Lisbon
Contact Information
Primary
Pedro Pinto
geral@phdtrials.com
+351 216034267
Time Frame
Start Date: 2024-02-19
Estimated Completion Date: 2024-05-22
Participants
Target number of participants: 60
Treatments
Experimental: mild to moderate melasma
adult patients suffering from mild to moderate melasma (Investigator's Global Assessment (IGA) 1 or 2)
Experimental: mild to moderate acne induced PIHP
adult patients suffering from mild to moderate acne-induced PIHP (IGA 1 or 2) without active acne (i.e., less than 10 inflammatory lesions)
Experimental: solar lentigo
adult patients suffering from solar lentigo with a pigmentation score \> 5
Related Therapeutic Areas
Sponsors
Leads: Cosmetique Active International